IRBM comprises the core medicinal chemistry team behind the discovery of the first-in-class HIV-Integrase inhibitor Isentress™. Strong organic synthesis experience underpins our medicinal chemistry efforts that take a highly focused and multidisciplinary approach toward the evolution of leads into developable drug candidates. Many of our key people are former employees of Merck Research Laboratories. The Medicinal Chemistry team has a strong know-how to advance compounds and extensive experience across different disease areas including oncology, anti-virals, diabetes, obesity, cardiovascular and CNS. We have a strong track record in delivering preclinical and clinical small molecule compounds. We provide services in many areas of medicinal chemistry: early lead identification, hit-to-lead evolution, lead optimization, and identification of preclinical candidates.